Alcon Ends PowerVision IOL Program and Books $402M Write-Off
Alcon has shut down its PowerVision intraocular lens technology program after recent clinical study results showed unpredictable postoperative outcomes. The termination triggered a $402 million write-off in the second quarter. Alcon bought PowerVision in 2019 for $285 million, and plans to keep investing in next-generation IOL technology while exploring joint adjustable presbyopia-correcting lenses with RxSight.